Seoul, South Korea & London, UK — 24 July 2025 – FLock.io, the Web3-native platform for decentralized, privacy-preserving AI, and AIGEN Sciences, the award-winning AI-driven drug-discovery company, today announced the signing of a Memorandum of Understanding (MoU) to integrate federated-learning technology with large-language-model-powered discovery tools, enabling pharmaceutical and clinical partners in South Korea to train AI models collaboratively without moving or exposing sensitive data.
Under the MoU the parties will connect FLock.io’s on-chain federated-learning infrastructure to AIGEN’s discovery engine, giving hospitals and research organizations a secure way to contribute real-world datasets while retaining full data control.
“This collaboration is an important milestone in making truly decentralized AI a reality for life-sciences,” said Jiahao Sun, Co-founder & CEO, FLock.io. “By pairing our blockchain-secured incentive layer with AIGEN’s proven drug-discovery stack, we can unlock high-value biomedical insights while upholding the strongest privacy standards.”
“AIGEN’s mission is to shorten the path from concept to clinic,” added Professor Jaewoo Kang, CEO, AIGEN Sciences. “FLock.io’s privacy-preserving technology lets us collaborate with hospitals and pharma companies on datasets that were previously off-limits. Together, we expect to deliver better medicines, faster.”
Dr. Zehua Cheng, Chief Scientist at FLock.io, and Dr. Sunkyu Kim, Director of AI Research at AIGEN, will co-lead the technical integration. Initial proof-of-concept studies are scheduled to begin in Q3 2025, with results to be shared at upcoming AI-for-healthcare conferences.
You can find the Korean version of this article here.
